Alnylam Pharmaceuticals, Inc. (ALNY) Reports Q4 Loss of $0.33
Tweet
Share
E-mailGet Alerts ALNY Hot Sheet
Price: $236.22 +3.02%
Financial Fact:
Net loss per common share - basic and diluted: -1.05
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Net loss per common share - basic and diluted: -1.05
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) reported Q4 EPS of ($0.33), $0.01 worse than the analyst estimate of ($0.32). Revenue for the quarter came in at $20.5 million versus the consensus estimate of $20.9 million.
For earnings history and earnings-related data on Alnylam Pharmaceuticals, Inc. (ALNY) click here.
For earnings history and earnings-related data on Alnylam Pharmaceuticals, Inc. (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Is the global equity rally broadening? UBS weighs in
- Bernstein remains bullish on SpaceX but sees challenges in telecom ambitions
- Morgan Stanley Starts Tier IV Inc (593A:JP) at Overweight
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
